Evidence map›Paper›PMID 39010317›Full record

ArticleESC heart failure2024

Personalized care in dilated cardiomyopathy: Rationale and study design of the activeDCM trial.

Farbod Sedaghat-Hamedani, Ali Amr, Theresa Betz, Elham Kayvanpour, Christoph Reich, Reto Wettstein, Oliver Heinze, Isabell Mohr, Regina Krisam, Anja Sander and 4 more

Abstract readClinical Trial Protocol
In one paragraph

Article in ESC heart failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Farbod Sedaghat-HamedaniMedical Faculty of the University Heidelberg, Institute for Cardiomyopathies Heidelberg (ICH), Department of Internal Medicine III, University Hospital Heidelberg, Heidelberg, Germany.
Ali AmrMedical Faculty of the University Heidelberg, Institute for Cardiomyopathies Heidelberg (ICH), Department of Internal Medicine III, University Hospital Heidelberg, Heidelberg, Germany.
Theresa BetzMedical Faculty of the University Heidelberg, Institute for Cardiomyopathies Heidelberg (ICH), Department of Internal Medicine III, University Hospital Heidelberg, Heidelberg, Germany.
Elham KayvanpourMedical Faculty of the University Heidelberg, Institute for Cardiomyopathies Heidelberg (ICH), Department of Internal Medicine III, University Hospital Heidelberg, Heidelberg, Germany.
Christoph ReichMedical Faculty of the University Heidelberg, Institute for Cardiomyopathies Heidelberg (ICH), Department of Internal Medicine III, University Hospital Heidelberg, Heidelberg, Germany.
Reto WettsteinInstitute of Medical Informatics, Heidelberg University Hospital, Heidelberg, Germany.
Oliver HeinzeInstitute of Medical Informatics, Heidelberg University Hospital, Heidelberg, Germany.
Isabell MohrMedical Faculty of the University Heidelberg, Institute for Cardiomyopathies Heidelberg (ICH), Department of Internal Medicine III, University Hospital Heidelberg, Heidelberg, Germany.
Regina KrisamInstitute of Medical Biometry, University of Heidelberg, Heidelberg, Germany.
Anja SanderInstitute of Medical Biometry, University of Heidelberg, Heidelberg, Germany.
Christina KloseInstitute of Medical Biometry, University of Heidelberg, Heidelberg, Germany.
Birgit Friedmann-BetteDepartment of Sports Medicine, Medical Clinic, University Hospital Heidelberg, Heidelberg, Germany.
Norbert FreyMedical Faculty of the University Heidelberg, Institute for Cardiomyopathies Heidelberg (ICH), Department of Internal Medicine III, University Hospital Heidelberg, Heidelberg, Germany.
Benjamin MederMedical Faculty of the University Heidelberg, Institute for Cardiomyopathies Heidelberg (ICH), Department of Internal Medicine III, University Hospital Heidelberg, Heidelberg, Germany.

Funding

Deutsche Herzstiftung (German Heart Foundation)
6 · The paper itself

Abstract

backgroundDilated cardiomyopathy (DCM) is a leading cause of heart failure, particularly in younger individuals. Low physical strength is a global risk factor for cardiovascular mortality, and physical activity and a healthy lifestyle have been shown to improve outcomes in patients with heart failure. However, inappropriate exercise may increase the risk of arrhythmias in certain individuals with DCM. The determinants for predicting individual risks in this setting are poorly understood, and clinicians are hesitant to recommend sports for cardiomyopathy patients. The activeDCM trial aims to assess the safety and efficacy of a personalized exercise and activity programme for individuals with DCM. STUDY

designThe activeDCM trial is a prospective, randomized, interventional trial with a 12 month follow-up. Three hundred patients, aged 18-75 years with DCM, left ventricular ejection fraction (LVEF) ≤ 50% and New York Heart Association (NYHA) classes I-III, will be enrolled. The intervention includes a personalized exercise and activity programme. The primary outcome is the increase in peak oxygen uptake (VO DISCUSSION: The activeDCM trial will provide valuable insights into the safety and efficacy of personalized exercise training in DCM patients, inform clinical practice and contribute to the development of heart failure management programmes. The study will generate data on the impact of exercise on various aspects of cardiovascular disease, including genetic, metabolic, phenotypic and longitudinal aspects, facilitating the development of future digital tools and strategies, including the incorporation of smart wearable devices.

Indexed as

Cardiomyopathy, DilatedPrecision MedicineAdolescentAdultAgedExercise TherapyFemaleFollow-Up StudiesHumansMaleMiddle AgedProspective StudiesQuality of LifeRandomized Controlled Trials as TopicStroke VolumeVentricular Function, LeftApple Watchdilated cardiomyopathyexerciseheart failurepersonalized trainingrandomized controlled trial

Identifiers

PMID39010317
PMCPMC11631299

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.